myirislogo
18 December, 2014 19:52 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
State Bank O 307.05 1.66
Ntpc 132.95 3.83
Hindalco In 153.60 4.31
Tata Stl 401.85 2.13
Sslt 203.75 1.44
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-GUFIC Biosciences Limited
GUFIC Biosciences Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:509079NSE:GUFICBIOBloomberg:CF@INReuters:GUFI.BO
Market Lot: 1Face Value: 1ISIN Demat: INE742B01025
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
17-JAN-11 Credit rating agency, CRISIL Equities has assigned a CRISIL IER fundamental grade of 2/5 to C&C Constructions (C&C). 14-SEP-10 C & C Constructions has entered into a formal joint venture agreement with Isolux Corsan of Spain on September 09, 2010. 05-MAY-10 Anagram has recommended `Buy` on C & C Construction with a price target of Rs 341 as against the market price (CMP) of Rs 238 in its report dated May. 5, 2010. 18-MAR-10 Anag...   More..
Business Profile Future Plans
CEO Talk
GUFIC Biosciences expects its turnover to increase by 57 per cent to Rs 63 crore in FY03. The company plans to intensify its R&D activity and raise Rs 20 crore through private placement.   Jayesh Choksi
One To One
Recent news
Latest News
  -
Previous

 


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)30-Sep-2014(6)31-Mar-2014 (12)31-Mar-2013 (12)
Net sales 817.191229.16999.83
Other Income1.734.922.16
Total Income818.921234.081001.99
Cost of goods sold736.791109.80892.58
OPBDIT82.13124.28109.41
PAT23.7942.6433.29
Gross Block---
Equity capital77.3577.3577.35
EPS (Rs.)-0.550.43
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-7.82 - 15.8011.86 - 22.05
Debt / Equity (x)---
Operating margin (% of OI)10.010.110.9
Net margin (% of OI) 2.9 3.5 3.3
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Gufic House
Subhash Road - A
Vile Parle (East)
Mumbai
Maharashtra-400 057
PHONE
(022) 6691 9187/ 89 - 93/ 6726 1007
FAX
(022) 2611 8103/ 2616 9008
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer